欧洲皮肤黑色素瘤生存率改善但区域差异持续:EUROCARE-6研究结果
该研究基于EUROCARE-6项目280,498例15岁以上侵袭性皮肤黑色素瘤患者(2008-2013年诊断,随访至2014年),采用完全队列法估算年龄标准化相对生存率(ASRS)并比较欧洲区域差异。欧洲5年ASRS为87.9%(95%CI 87.7-88.1%),中欧最高(91.2%),东欧最低(75.0%)。2003-2011年生存率略有上升,东欧及爱尔兰和英国改善最明显,但东西欧差距仍未显著缩小。
要点
- 欧洲皮肤黑色素瘤5年ASRS为87.9%,区域间从东欧75.0%到中欧91.2%不等。
- 女性5年相对生存率高于男性,且随年龄增长而下降。
- 2003-2011年生存率小幅改善,东欧及爱尔兰和英国改善最明显。
核心结论
- 欧洲皮肤黑色素瘤生存率较高且仍在改善,但东欧与欧洲平均水平的差距持续存在且未显著缩小。
研究设计与样本
- 基于EUROCARE-6项目的队列研究,纳入280,498例15岁以上侵袭性皮肤黑色素瘤患者(2008-2013年诊断,随访至2014年),采用完全队列法估算1年、5年及5年/1年条件年龄标准化相对生存率(ASRS)并进行地理比较。
- 采用时期法分析306,715例患者2003-2011年的生存时间趋势。
主要发现
- 欧洲5年ASRS为87.9%(95%CI 87.7-88.1%)。
- 5年ASRS中欧最高(91.2%;95%CI 90.9-91.6%),北欧90.3%(95%CI 89.7-90.9%),爱尔兰和英国89.2%(95%CI 88.9-89.6%),南欧85.7%(95%CI 85.2-86.2%),东欧最低(75.0%;95%CI 74.2-75.7%)。
- 区域内国家间5年ASRS绝对差异从北欧的2.9%到东欧的24.7%不等。
- 女性5年相对生存率高于男性,且随年龄增长而下降。
- 2003-2011年生存率略有上升,北欧改善较小,东欧及爱尔兰和英国改善最明显。
临床怎么用
- 临床应关注皮肤黑色素瘤生存率的区域差异,尤其东欧地区需加强从诊断到治疗的全临床路径改进。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to update previous EUROCARE survival estimates for skin melanoma (SM) monitoring trends and survival differences between European regions. METHODS: 1-year, 5-year, and 5-year/1-year conditional age-standardised relative survival (ASRS) and geographical comparisons were estimated on 280,498 patients participating in the EUROCARE-6 project (>=15 years old) with invasive SM (diagnosed 2008-2013; followed-up till 2014), applying a complete cohort approach. Survival time trends during 2003-2011 were analysed using the period approach for 306,715 patients. Survival analysis was estimated by age, gender, anatomical sub-sites and morphology subgroups. RESULTS: Among European patients 5-year ASRS estimate was 87.9 % (95 % confidence interval, CI 87.7-88.1 %). The highest values were measured in Central Europe (91.2 %; 90.9-91.6 %), Northern Europe (90.3 %; 89.7-90.9 %), Ireland and United Kingdom (89.2 %; 88.9-89.6 %), followed by Southern Europe (85.7 %; 85.2-86.2 %), while the lowest survival value was observed in Eastern Europe (75.0 %; 74.2-75.7 %). Within regions, the intercountry absolute difference in 5-year ASRS percentage points varied from 2.9 % (Northern Europe) to 24.7 % (Eastern Europe). Five-year RS was higher in women than men and decreased with patients' advancing age. Differences emerged in terms of SM morphology and skin sub-sites. Survival slightly increased from 2003 to 2011, with a small improvement in Northern and the most pronounced one in Eastern Europe and Ireland and UK. DISCUSSION: In Europe SM survival is high and still increasing. The gap between European average survival value and Eastern European countries is still present and has not diminished significantly yet. Improvements are needed in the whole SM clinical path, from diagnosis to therapy, to overcome differences across countries.
引用
- Crocetti E, Bennett D, Jooste V, et al. Skin melanoma survival is improving in Europe but regional differences persist: Results of the EUROCARE-6 study. Eur J Cancer. 2025. PMID: 41172568. doi:10.1016/j.ejca.2025.116061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。